1.Male or female with above 45 years of age, at the time of providing informed <br/ >consent. <br/ >2. Agreement to take effective contraception measures (including hormonal <br/ >contraception, barrier methods or abstinence) with his/her partner during the study <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or <br/ >oropharyngeal swabs (sample collected â?¤5 days prior to randomization) or CT <br/ >score CORADS III. <br/ >Note: If rapid antigen test has been performed and patient found positive then RT PCR will be performed prior to enrollment. <br/ >4. Has moderate to severe COVID-19 infection as defined as (with any one of the <br/ >following signs) <br/ >a. Respiratory rate â?¥ 24 and Ë?30/min, breathlessness <br/ >b. Oxygen saturation <93% without O2 support or patients requiring > <br/ >4L/Min of O2 <br/ >As defined by AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring <br/ >Group (Directorate General of Health Services) Ministry of Health & Family <br/ >Welfare, Government of India- clinical guidance for management of adult <br/ >COVID-19 patients, dated 22nd Apr 2021 <br/ >5. Is willing and able to take Radiation Therapy. <br/ >6. Raised CRP at the time of admission <br/ >7. Symptom onset less than 10 days or fewer. <br/ >8. CT Chest finding suggestive of pneumonic changes. <br/ >9. CT Severity index more than 8/25 (Moderate) <br/ >10. Willingness to comply with study instructions for its duration as indicated by <br/ >written informed consent from the patient/ LAR (in case LAR provides consent <br/ >initially, consent from patient to be obtained again as and when his/ her condition <br/ >stabilizes adequately). <br/ >11. Negative urine pregnancy test prior to beginning the therapy for female patients of <br/ >child-bearing potential only <br/ >

1.Male or female with above 45 years of age, at the time of providing informed <br/ >consent. <br/ >2. Agreement to take effective contraception measures (including hormonal <br/ >contraception, barrier methods or abstinence) with his/her partner during the study <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or <br/ >oropharyngeal swabs (sample collected â?¤5 days prior to randomization) or CT <br/ >score CORADS III. <br/ >Note: If rapid antigen test has been performed and patient found positive then RT PCR will be performed prior to enrollment. <br/ >4. Has moderate to severe COVID-19 infection as defined as (with any one of the <br/ >following signs) <br/ >a. Respiratory rate â?¥ 24 and Ë?30/min, breathlessness <br/ >b. Oxygen saturation <93% without O2 support or patients requiring > <br/ >4L/Min of O2 <br/ >As defined by AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring <br/ >Group (Directorate General of Health Services) Ministry of Health & Family <br/ >Welfare, Government of India- clinical guidance for management of adult <br/ >COVID-19 patients, dated 22nd Apr 2021 <br/ >5. Is willing and able to take Radiation Therapy. <br/ >6. Raised CRP at the time of admission <br/ >7. Symptom onset less than 10 days or fewer. <br/ >8. CT Chest finding suggestive of pneumonic changes. <br/ >9. CT Severity index more than 8/25 (Moderate) <br/ >10. Willingness to comply with study instructions for its duration as indicated by <br/ >written informed consent from the patient/ LAR (in case LAR provides consent <br/ >initially, consent from patient to be obtained again as and when his/ her condition <br/ >stabilizes adequately). <br/ >11. Negative urine pregnancy test prior to beginning the therapy for female patients of <br/ >child-bearing potential only <br/ >

1.Male or female with above 45 years of age, at the time of providing informed <br/ >consent. <br/ >2. Agreement to take effective contraception measures (including hormonal <br/ >contraception, barrier methods or abstinence) with his/her partner during the study <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or <br/ >oropharyngeal swabs (sample collected â?¤5 days prior to randomization) or CT <br/ >score CORADS III. <br/ >Note: If rapid antigen test has been performed and patient found positive then RT PCR will be performed prior to enrollment. <br/ >4. Has moderate to severe COVID-19 infection as defined as (with any one of the <br/ >following signs) <br/ >a. Respiratory rate â?¥ 24 and Ë?30/min, breathlessness <br/ >b. Oxygen saturation <93% without O2 support or patients requiring > <br/ >4L/Min of O2 <br/ >As defined by AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring <br/ >Group (Directorate General of Health Services) Ministry of Health & Family <br/ >Welfare, Government of India- clinical guidance for management of adult <br/ >COVID-19 patients, dated 22nd Apr 2021 <br/ >5. Is willing and able to take Radiation Therapy. <br/ >6. Raised CRP at the time of admission <br/ >7. Symptom onset less than 10 days or fewer. <br/ >8. CT Chest finding suggestive of pneumonic changes. <br/ >9. CT Severity index more than 8/25 (Moderate) <br/ >10. Willingness to comply with study instructions for its duration as indicated by <br/ >written informed consent from the patient/ LAR (in case LAR provides consent <br/ >initially, consent from patient to be obtained again as and when his/ her condition <br/ >stabilizes adequately). <br/ >11. Negative urine pregnancy test prior to beginning the therapy for female patients of <br/ >child-bearing potential only <br/ >

1.Male or female with above 45 years of age, at the time of providing informed <br/ >consent. <br/ >2. Agreement to take effective contraception measures (including hormonal <br/ >contraception, barrier methods or abstinence) with his/her partner during the study <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or <br/ >oropharyngeal swabs (sample collected â?¤5 days prior to randomization) or CT <br/ >score CORADS III. <br/ >Note: If rapid antigen test has been performed and patient found positive then RT PCR will be performed prior to enrollment. <br/ >4. Has moderate to severe COVID-19 infection as defined as (with any one of the <br/ >following signs) <br/ >a. Respiratory rate â?¥ 24 and Ë?30/min, breathlessness <br/ >b. Oxygen saturation <93% without O2 support or patients requiring > <br/ >4L/Min of O2 <br/ >As defined by AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring <br/ >Group (Directorate General of Health Services) Ministry of Health & Family <br/ >Welfare, Government of India- clinical guidance for management of adult <br/ >COVID-19 patients, dated 22nd Apr 2021 <br/ >5. Is willing and able to take Radiation Therapy. <br/ >6. Raised CRP at the time of admission <br/ >7. Symptom onset less than 10 days or fewer. <br/ >8. CT Chest finding suggestive of pneumonic changes. <br/ >9. CT Severity index more than 8/25 (Moderate) <br/ >10. Willingness to comply with study instructions for its duration as indicated by <br/ >written informed consent from the patient/ LAR (in case LAR provides consent <br/ >initially, consent from patient to be obtained again as and when his/ her condition <br/ >stabilizes adequately). <br/ >11. Negative urine pregnancy test prior to beginning the therapy for female patients of <br/ >child-bearing potential only <br/ >